SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bristol-Myers Squibb Company: Orencia(R) (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years

June 12, 2009 | 
1 min read
COPENHAGEN--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of two ORENCIA® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held in Copenhagen, Denmark.
Clinical research Phase 2 Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
IgA nephropathy
Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data
June 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Lymphoma
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
June 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Rethinking hair loss treatment
June 4, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Futuristic digital speedometer with glowing lines and red needle, representing fast acceleration and advanced automotive technology. vector eps10
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
June 3, 2026
 · 
2 min read
 · 
Gabrielle Masson